RxDoctor Payments DataLook up a doctor →

Rana Hasan, MD

Pulmonary Disease · Smyrna, GANPI 1194708651

Payments from drug & device makers

$74,565in general payments, 2019–2025

Across 975 payments — averaging $76.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$39K
  • Mylan Specialty L.p.$11K
  • Sunovion Pharmaceuticals Inc.$10K
  • GSK$2K
  • Boehringer Ingelheim$2K
  • Jazz Pharmaceuticals Inc.$1K
  • plus $10K from 47 others

What the payments were for

  • Consulting fees$3,0654%
  • Speaking & faculty fees$47,03763%
  • Travel & lodging$4,7526%
  • Food & beverage$19,42626%
  • Education$2850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,565 in reported general payments places this provider in the 85th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$73,597
Medicare patients
300
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate20$334,821
WakixPitolisant Hcl11$174,827
Trelegy ElliptaFluticasone/Umeclidin/Vilanter171$141,008
Spiriva RespimatTiotropium Bromide50$39,017
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$36,599
Breo ElliptaFluticasone/Vilanterol79$30,779
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$26,040
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$17,254
EliquisApixaban15$10,845
SymbicortBudesonide/Formoterol Fumarate27$8,390
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$7,991
Advair HfaFluticasone Propion/Salmeterol14$5,316
Albuterol Sulfate HfaAlbuterol Sulfate210$4,461
Incruse ElliptaUmeclidinium Bromide11$3,829
Wixela InhubFluticasone Propion/Salmeterol43$3,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$2,020$204,893323 claims
Harmony Biosciences LLCWakix$1,016$174,82711 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,739$56,27267 claims
AstraZenecaBreztri Aerosphere, Symbicort$38,786$44,98980 claims
PfizerEliquis$64$10,84515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →